Peer-influenced content. Sources you trust. No registration required. This is HCN.
Psychiatrist.com
A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.
Behavioral Health September 25th 2026
MDLinx
A report examining a celebrity-backed sports prediction campaign highlights concerns about increasing youth exposure to gambling-related marketing. The article connects growing gambling participation among adolescents and young adults with evidence linking gambling disorder to adverse mental health outcomes, including suicidality.
Adolescent Medicine September 24th 2026
Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.
Psychiatric Pharmacy (BCPP) July 31st 2026
Psychiatry Advisor
Suicide mortality increased among adolescents and young adults across the Americas from 2000 to 2021. Rates varied by age, sex, and region, with widening disparities observed in population-level data.
Child & Adolescent Psychiatry June 23rd 2026
A single 25-mg dose of synthetic psilocybin with structured psychological support produced rapid, large-magnitude reductions in suicidal ideation through 12 weeks in 20 treatment-resistant adults with major depressive disorder, with two participants experiencing worsening ideation.
Psychiatry June 9th 2026
Adjunctive cognitive behavioral therapy reduced depressive symptoms and ideation scores versus treatment as usual in a 93-patient feasibility trial of esketamine for major depression with suicidal ideation.
Psychiatry May 27th 2026